Cargando…
Vaccines against COVID-19: Priority to mRNA-Based Formulations
As of September 2021, twenty-one anti-COVID-19 vaccines have been approved in the world. Their utilization will expedite an end to the current pandemic. Besides the usual vaccine formats that include inactivated viruses (eight approved vaccines) and protein-based vaccines (four approved vaccines), t...
Autor principal: | Pascolo, Steve |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534873/ https://www.ncbi.nlm.nih.gov/pubmed/34685696 http://dx.doi.org/10.3390/cells10102716 |
Ejemplares similares
-
Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients
por: Romano, Emanuela, et al.
Publicado: (2021) -
CEC01-02 Development of mRNA-based vaccines
por: Pascolo, S.
Publicado: (2022) -
Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes
por: Mayer, Rupert L., et al.
Publicado: (2022) -
COVID-19 mRNA vaccines
por: Huang, Qingrui, et al.
Publicado: (2021) -
mRNA Vaccines against Flaviviruses
por: Wollner, Clayton J., et al.
Publicado: (2021)